title: Peripheral ammonia as a mediator of methamphetamine neurotoxicity.
abstract: Ammonia is metabolized by the liver and has established neurological effects. The current study examined the possibility that ammonia contributes to the neurotoxic effects of methamphetamine (METH). The results show that a binge dosing regimen of METH to the rat increased plasma and brain ammonia concentrations that were paralleled by evidence of hepatotoxicity. The role of peripheral ammonia in the neurotoxic effects of METH was further substantiated by the demonstration that the enhancement of peripheral ammonia excretion blocked the increases in brain and plasma ammonia and attenuated the long-term depletions of dopamine and serotonin typically produced by METH. Conversely, the localized perfusion of ammonia in combination with METH, but not METH alone or ammonia alone, into the striatum recapitulated the neuronal damage produced by the systemic administration of METH. Furthermore, this damage produced by the local administration of ammonia and METH was blocked by the GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzamine hydrochloride], an AMPA receptor antagonist. These findings highlight the importance of ammonia derived from the periphery as a small-molecule mediator of METH neurotoxicity and more broadly emphasize the importance of peripheral organ damage as a possible mechanism that mediates the neuropathology produced by drugs of abuse and other neuroactive molecules.
authors.affiliation: Department of Neurosciences, University of Toledo College of Medicine, Toledo, Ohio 43614, USA.
authors.forename: Laura E
authors.initials: LE
authors.lastname: Halpin
authors.forename: Bryan K
authors.initials: BK
authors.lastname: Yamamoto
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000641:Ammonia / Q000378:metabolism / Q000627:therapeutic use*; D000704:Analysis of Variance; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001569:Benzodiazepines / Q000008:administration & dosage; D015306:Biogenic Monoamines / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000633:toxicity*; D002851:Chromatography, High Pressure Liquid; D004195:Disease Models, Animal; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism; D005334:Fever / Q000150:complications / Q000209:etiology; D005786:Gene Expression Regulation / Q000187:drug effects; D007792:Lactulose / Q000008:administration & dosage; D008107:Liver Diseases / Q000209:etiology; D008297:Male; D013058:Mass Spectrometry; D008694:Methamphetamine / Q000633:toxicity*; D017551:Microdialysis; D018696:Neuroprotective Agents / Q000008:administration & dosage; D020258:Neurotoxicity Syndromes / Q000150:complications / Q000188:drug therapy* / Q000209:etiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
chemical_list: D015306:Biogenic Monoamines; D000697:Central Nervous System Stimulants; D050483:Dopamine Plasma Membrane Transport Proteins; D018696:Neuroprotective Agents; C061950:GYKI 52466; D001569:Benzodiazepines; D008694:Methamphetamine; D007792:Lactulose; D000641:Ammonia; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase